The anti-inflammatory drug, tocilizumab, improves survival for patients hospitalised with covid-19, shortens the time to discharge, and reduces the need for a mechanical ventilator, results from the randomised evaluation of covid-19 therapy (Recovery) trial show. For every 25 patients treated with tocilizumab, one additional life would be saved, according to the researchers from Oxford University. Previous trials on tocilizumab have yielded inconclusive results. However, because the Recovery trial is four times larger than all of the other studies combined, the benefits are now obvious. For more details please read here: https://www.bmj.com/content/372/bmj.n433 If you find this research insightful, please like, comment and share.